Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

  title={Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.},
  author={Stephan Heres and John Davis and Katja Maino and Elisabeth Jetzinger and Werner Kissling and Stefan Leucht},
  journal={The American journal of psychiatry},
  volume={163 2},
OBJECTIVE In many parts of the world, second-generation antipsychotics have largely replaced typical antipsychotics as the treatment of choice for schizophrenia. Consequently, trials comparing two drugs of this class--so-called head-to-head studies--are gaining in relevance. The authors reviewed results of head-to-head studies of second-generation antipsychotics funded by pharmaceutical companies to determine if a relationship existed between the sponsor of the trial and the drug favored in the… 

Figures and Tables from this paper

Olanzapine versus other atypical antipsychotics for schizophrenia.

Olanzapine improved the general mental state (PANSS total score) more than aripiprazole, but not more than amisulpride or clozapine, and less than quetiapine or ziprasidone in people with schizophrenia or schizophrenia-like psychosis.

Risperidone versus other atypical antipsychotics for schizophrenia.

Risperidone produced somewhat more extrapyramidal side effects than a number of other SGAs and was slightly less acceptable than olanzapine, and slightly more acceptable than ziprasidone in this regard.

Ziprasidone versus other atypical antipsychotics for schizophrenia.

Ziprasidone was a less acceptable treatment than olanzapine and less efficacious than amisulpride, but not than the other second generation antipsychotic drugs.

Zotepine versus other atypical antipsychotics for schizophrenia.

The evidence base around zotepine is insufficient to provide firm conclusions on its absolute or relative effects, and this is despite it being in use in Austria, France, Germany, Japan and the UK.

Aripiprazole versus other atypical antipsychotics for schizophrenia.

Aripiprazole may be somewhat less effective than olanzapine, but more tolerable in terms of metabolic effects and sedation, and there is no evidence for a difference in efficacy compared to risperidone, but for better tolerability in Terms of dystonias, cholesterol prolactin increase and QTc prolongation.

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.

Combining SGAs and MSs is the most efficacious treatment of acute mania, and adding antipsychotic agents to MS treatment was significantly more effective than treatment with MSs alone.

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone

Quetiapine appears to be a good starting drug candidate in this sample of patients admitted to hospital for symptoms of psychosis, and performed equally with regards to most tolerability outcomes.

Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications

Olanzapine demonstrated superior real-world effectiveness over risperidone, in terms of survival and psychiatric hospitalization, in a national non-concurrent cohort with 16 years of follow-up.



Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

Olanzapine seemed to have a risk-versus-benefit advantage in the management of psychotic symptoms, and the differential preclinical profiles of these two drugs were also evident in a controlled, clinical investigation.

Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.

Clozapine was superior to risperidone for positive symptoms and parkinsonian side effects, but there were no significant differences between the drugs on two measures of negative symptoms, Brief Psychiatric ratings total scores, and depression scores.

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.

  • J. Jerrell
  • Psychology, Medicine
    Schizophrenia bulletin
  • 2002
Findings extend findings from previous efficacy and naturalistic studies in several ways but are limited chiefly by the small number of subjects who completed 6 to 12 months of the clinical trial, and the resulting power to detect differences in the statistical analyses.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Great reductions in severity of positive and affective symptoms were seen with risperidone than with olanzapine treatment among study completers, and both treatments were well tolerated and efficacious.

Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder

Improvements seen in total and negative symptom scores with clozapine and olanzapine were superior to haloperidol and the effects of atypical antipsychotics in this population were statistically significant.

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

Risperidone was well tolerated and as effective as medium doses of clozapine in patients with chronic schizophrenia who had been resistant to or intolerant of conventional neuroleptics.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

The overall pattern of results suggests that clozapine and olanzapine have similar general antipsychotic efficacy and that risperidone may be somewhat less effective.